CANDEL THERAPEUTICS INC (CADL) Stock News

USA - Nasdaq - NASDAQ:CADL - US1374041093 - Common Stock

4.43 USD

-0.1 (-2.21%)

Last: 11/25/2025, 12:53:36 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CADL Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Candel Therapeutics

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

8 days ago - By: Candel Therapeutics

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

12 days ago - By: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

12 days ago - By: Candel Therapeutics - Mentions: TRIN

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: Stocktwits - Mentions: VTWG URTY

News Image

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer

3 months ago - By: The Motley Fool

Candel Reports 88 Percent Q2 Loss Drop

21 days ago - By: Candel Therapeutics

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

21 days ago - By: Candel Therapeutics

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

22 days ago - By: Candel Therapeutics

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

22 days ago - By: Candel Therapeutics

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

a month ago - By: Benzinga - Mentions: VDC XLP TRIN ABT ...

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards

a month ago - By: Candel Therapeutics

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

a month ago - By: Candel Therapeutics

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

a month ago - By: Benzinga - Mentions: BCRX XNCR SNTI ADAP ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Trinity Capital Inc. - Mentions: TRIN

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

a month ago - By: Candel Therapeutics

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

a month ago - By: Candel Therapeutics - Mentions: TRIN

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

a month ago - By: Candel Therapeutics

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

a month ago - By: Candel Therapeutics

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

2 months ago - By: Candel Therapeutics

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

2 months ago - By: Candel Therapeutics

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

2 months ago - By: Candel Therapeutics

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

3 months ago - By: Candel Therapeutics

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

3 months ago - By: Candel Therapeutics

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

3 months ago - By: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

3 months ago - By: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

3 months ago - By: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

3 months ago - By: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

4 months ago - By: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

4 months ago - By: Candel Therapeutics

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

4 months ago - By: Candel Therapeutics

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

5 months ago - By: Candel Therapeutics

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution